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Abstract
Nelson, Deidra Diane. M.S. The University of Memphis. May 2014. Probiotics
lactobacillus plantarum 299v and bifidobacteria b107 in the prevention of hospital associated
infections: a retrospective cohort study. Major Professor: Dr. Ruth Williams-Hooker.

Hospital acquired infections (HAI) are associated with increased mortality, morbidity and costs.
Medical Intensive Care Unit (MICU) patients have increased risk for HAI. Probiotics may be
beneficial in reducing HAI. A retrospective cohort study was completed to determine the effect
of food form probiotics in the prevention of HAI among MICU patients. Patients received
probiotic containing 50 billion colony forming units daily for periods of 24 hours to 93 days.
Infection rates three years prior, eight months during and one year post probiotic implementation
were collected and compared with incidence of HAI in the same patient population. Significant
differences in the incidence of central line associated bloodstream infection, ventilator associated
pneumonia and Clostridium difficile associated diarrhea (CDAD) were indicated between control
one, the experimental group, and control two using Chi square analysis. Food form probiotics
were determined to be effective at reducing rates of CDAD in MICU patients.
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CHAPTER 1: INTRODUCTION

Hospital acquired infections (HAI) are of great concern because such infections
are associated with increased mortality, morbidity and financial costs (5). Ventilator
associated pneumonia (VAP), Clostridium difficile associated diarrhea (CDAD),
antibiotic associated diarrhea (AAD), and central line associated bloodstream infections
(CLABSI) are the most costly HAI (42). Annually, 1.7 million HAIs are reported in
United States hospitals and 100,000 deaths occur annually in patients with HAIs (14).
HAIs are estimated to cost 17-20 billion dollars each year (14). Patients, particularly the
elderly, in the Medical Intensive Care Unit (MICU) are at a higher risk for developing
these HAI infections because they are typically sicker than their younger counterparts and
require multiple interventions (25). These interventions include broad spectrum
antibiotics, gastric acid suppressants, and other medications that alter gut mobility (25).
This altered gut mobility may lead to decreased host defense and colonization by
pathogenic bacteria, which in turn leads to increased risk of infection (5). Although
many antibiotic therapies have been studied in decreasing the infection rate of VAP,
CDAD, AAD, and CLABSI, there is an increase in antibiotic resistance to these
infections and there are few new antibiotics available for use (34). Probiotics may be
beneficial in optimizing host immune defenses and minimizing more dangerous bacteria
species involved in HAI, but unfortunately, they have not been heavily researched in the
prevention of VAP, CDAD, and CLABSI (34).
Probiotics are living microorganisms that provide benefits to the host when
ingested (34). They are able to survive in the human gastrointestinal tract (GIT) because
of their ability to tolerate acid and bile (4). Probiotics have three functions: suppression
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of growth or epithelial binding/invasion by pathogenic bacteria; improving the intestinal
barrier function, causing production of protective cytokines and modulation of the
immune system, suppressing intestinal pro-inflammatory cytokines (3). Benefits include
decreased susceptibility to pathogens and shortened duration of infection (4). Probiotics
are beneficial for not only gastrointestinal disorders, but also for respiratory, urogenital,
oral health and allergic diseases (4). Research has shown when digestive flora is lost due
to infection it can be restored by implementing probiotics into the gut (4). Because of
this, HAI, infection rates may be reduce by the addition of probiotics into the human GIT
(4).
One infection that may be reduced by probiotics is VAP. Prolonged mechanical
ventilation (MV) has been found to cause VAP in most ICU patients; however, some
patients develop pneumonia in less than 48 hours after intubation (34). VAP rates are
higher for patients in ICUs than in general medicine wards (34). VAP involves
colonization of the aerodigestive tract with pathogenic bacteria (34). “VAP is defined as
an inflammation of the lung parenchyma caused by infectious agents not present or
incubating at the time MV was started” (34). Probiotics may be able to reduce the
incidence of VAP through multiple effects that optimize host immune defenses (34).
CDAD may also be reduced through probiotic implementation. Clostrdium
difficile is the leading cause of diarrhea in hospitalized patients. In 2002, it was estimated
that this disease cost over 1 billion dollars annually in hospitalized patients (3). Diarrhea
is also more common among patients in the ICU because of broad spectrum antibiotic
use, leading to AAD (3). Clostridium difficile is a bacterium that spreads through the
fecal oral route (25). It is most always related to the use of antibiotics, which is a reason
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to find an alternate therapy to treat this diarrhea. Other risk factors include age, enteral
feeding tube use, and prior hospitalization (25). Diarrhea results in loss of fluid and
electrolytes which negatively impacts nutritional status, wound healing and skin integrity
(26).
CLABSI is a central line associated blood stream infection, but probiotics
have not been well studied in its’ prevention. Mishandling of intravenous catheters is
the largest cause of this infection (33). One key way to avoid this infection is through
proper placement of catheters (33). However, if the infection has already developed,
there is a possibility that probiotics could help in the healing process of the infection
as well.
VAP, CDAD, and CLABSI all increase morbidity and mortality in critically ill
patients (25,33,25). It is important to find treatments that lower morbidity and
mortality rates to decrease length of stay and prolong the lives of patients. Probiotics
have potential to be of benefit to patients in the MICU who have these infections. For
this reason, a retrospective study was performed to establish what, if any, effect
probiotics have on the infection rate of MICU patients with CDAD, VAP, and
CLABSI.
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CHAPTER 2: LITERATURE REVIEW

Probiotics are an emerging area of research because of the effect they may have
on hospital associated infections (HAI). Probiotics are, as defined by the World Health
Organization, “viable microorganisms that, when ingested in a sufficient amount can be
beneficial for health” (4). A microorganism is considered a probiotic if it can survive
through the stomach’s bile and acid and reach the intestines to be beneficial (4). There
are many different strains and species of probiotics, all of which have varying effects on
intestinal microbiota. The most common are Lactobacillus and Bifidobacteria species
(4). This literature review will focus on probiotics’ effect on Ventilator Associated
Pneumonia (VAP), Antibiotic Associated Diarrhea (AAD), Clostridium difficile
Associated Diarrhea (CDAD), and Central Line Associated Blood Stream Infection
(CLABSI). Each of these HAI are costly and increase patient risk for mortality (4,42). In
2007, it was estimated that two-thirds of deaths from HAIs were caused by catheter
associated blood stream infections (CABSI) (also known as CLABSI) and VAP, and
these two infections are five times more deadly than any other HAI (42). VAP cases that
are preventable range from 2.19 billion to 3.17 billion dollars annually (42). Probiotics
have been shown to be effective in many different infections that are hospital associated
(4).

Ventilator Associated Pneumonia
VAP occurs in 30% of patients on mechanical ventilation (5). VAP is defined as
nosocomial pneumonia that usually develops after 48 hours of endotracheal intubation
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(5). VAP is diagnosed either clinically or microbiologically. Microbiologically, the
bacteria isolated most in VAP are gram negative organisms, but gram positive organisms
are occasionally seen (5). The isolated organisms are directly related to hospital
admission (5). Those patients in the ICU are at higher risk of getting VAP because they
are more likely to require intubation (5). Once a patient is hospitalized, the oropharynx
can become colonized by bacteria, and if a patient aspirates them, they enter the
respiratory tract (37). If the airways become colonized by the bacteria, and it takes over
natural host defenses, VAP occurs (37). Currently prevention mechanisms include
avoiding intubation if possible, reducing time of mechanical ventilation, or using non
invasive ventilation (37).
The studies using probiotics for reduction of VAP have had mixed results. In
2010, a study on prophylaxis of VAP using probiotics was published by Barraud et al and
no clear recommendations were made (5). Patients were included if they were expected
to be on ventilation for at least 2 days. This study used Ergyphilus® capsules that
contained Lactobacillus rhamnosus GG, Lactobacillus casei, Lactobacillus acidolphus,
and Bifidobacterium bifidum. All patients received the same enteral nutrition and the
demographics of both the placebo and treatment group were similar. In this study, VAP
was defined as, “a new and persistent infiltrate on chest radiograph associated with at
least one of the following: purulent tracheal secretions, temperature 38.3˚C or higher, and
a leukocyte count of 10,000 lL-1 or higher; and (b) positive quantitative cultures of distal
pulmonary secretions obtained from bronchoalveolar lavage” (5). A total of 167 patients
participated in the study done between 2006 and 2008, for 28 days. Mortality rates were
not significantly different in the probiotic group (25.3%) and the placebo group (23.7%).
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A decline in catheter related blood stream infections was noted in the probiotic group
(1.84% vs 6.78%). However, probiotics were not shown to reduce VAP. This study also
found that when probiotics were given to non severe sepsis patients, there was a higher
risk of death. This was most likely due to poor hygiene practices leading to patients being
exposed to other bacteria aside from the probiotics. Fortunately, there were no reported
side effects caused by the probiotics in this study which is reason for their
implementation. Ultimately the researchers concluded that probiotics should not be used
in the critically ill patient because protective effects could not be determined and
uncertainties still remain. Although this study did not find probiotics to be preventative
against VAP, another study using ventilated patients did find that probiotic Lactobacillus
rhamnosus GG reduced VAP (5, 35).
Morrow et al. conducted a prospective randomized double blind placebo
controlled trial of the effect of probiotics in 146 mechanically ventilated patients (35).
All participants required intubation for at least 72 hours and antibiotics were given at
investigator discretion. The primary outcome was the reduction of VAP and the
secondary outcome was the reduction of CDAD. In this study, Lactobacillus rhamnosus
GG was selected and it was administered at 2 x 510 CFU. The results showed that in this
high risk population, probiotics were beneficial in preventing VAP. In the study, 33 out
of 70 patients in the placebo group were clinically diagnosed with VAP and 17/68 in the
treatment group were diagnosed. “Although VAP caused by gram-positive organisms did
not differ between groups (12.8 vs. 5.8%; P50.16), cases of VAP caused by gram–
negative organisms were dramatically different (22.8 vs. 8.8%; P , 0.02)” (35). The
secondary outcomes of the study found that probiotics led to a delay in onset of
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microbiologically confirmed VAP and reduced rates of CDAD. In the placebo group
18.6% of participants developed CDAD while only 5.8% in the treatment group
developed the infection.
Morrow’s study showed that probiotics can be beneficial in preventing VAP (35).
It differed from the Barraud study, which could not conclude benefits, in the amount of
probiotic administered and the type of probiotic. In the Morrow study, specifically
Lactobacillus GG was used. Barraud et al. used a combination of three types of
probiotics. Less CFU were used in the study that found reduction of VAP (5).
Therefore, it is very possible that variations in the amount and type of probiotic impact
the rates of VAP in critically ill patients as well as CDAD as evidenced by the two
studies.

Antibiotic Associated Diarrhea and Clostridium difficle Associated Diarrhea
CDAD is a bacterium diarrhea caused by C.difficile and C.difficile is estimated to
cause 10-25% of most AAD cases and annually, CDAD totals around 3.2 billion dollars
to the health care industry in the US (22, 26). Once the bacterium is found in AAD, it
becomes CDAD. Broad spectrum antibiotics are the main cause of AAD and CDAD,
although advanced age and poor general condition also contribute (40). The standard
treatment for C. difficile is discontinuation of the offending antibiotic and dietary
maintenance, but these treatments are often ineffective in severe cases (40, 19). Even
worse, about one in four patients who develop CDAD will relapse within 2 months (40,
19). Probiotics may reduce AAD and CDAD by suppressing pathogenic bacteria
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colonization. While some studies have supported this claim, others could not draw
conclusions (19).
Song et al. completed a study using probiotics on AAD that did not result
significant findings (40). In 2010, the Journal of Korean Medical Sciences published
their study on the effects of Lactobacillus (Lacidofil Cap®) on AAD. It was a
prospective, randomized, double blind trial in patients with respiratory tract infections.
Two-hundred and fourteen subjects passed screening but only 172 completed the trial.
The subjects who were being given antibiotics were randomized into the placebo or
Lactobacillus (Lacidofil Cap®) groups. Those participating in the study recorded their
stool frequencies and consistency every day for 14 days. There were two potential
outcomes, AAD-1 and AAD-2. AAD-1 was defined as, “loose or watery stools more than
3 times per day for at least 2 days within 14 days of enrollment” (40). AAD-2 consisted
of, “loose or watery stools more than 2 times per day for at least 2 days within 14 days of
enrollment” (40). Participants either received placebo or Lacidofil Cap. The Lacidofil
Cap® contains, L. rhamnosus R0011, L. acidophilus R0052 bacterial culture (2×109
colony-forming units), maltodextrin, Mg stearate, and ascorbic acid. The placebo group
received a tablet of maltodextrin, Mg stearate and ascorbic acid. Either the placebo or
probiotic were given within 48 hours after the start of antibiotics. Each group received
their specific capsule twice per day. The demographics and medical profiles of the
subjects were similar in both groups. The antibiotics that were administered included
cephalosporin, macrolides, fluoroquniolones, antituberculosis drugs, clindamycin and
penicillin. There was no significance in the antibiotic selections. After analyzing the
results, this study found that AAD-1 occurred in 3.9% of the study group and 7.2% in the
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placebo group. AAD-2 occurred in 8.7% of the study group and 14.4% of the placebo
group. Participants were only followed up for 2 weeks after treatment, but AAD has
been shown to occur up to two months after antibiotic treatment. Although more people
in the placebo group developed AAD, the study was limited by poor follow up.
Therefore, probiotic use in AAD could not be definitively recommended based on the
data.
The amount of probiotic needed to prevent AAD was not known when the
previous study was completed, so another study, done by Gao et al. used a randomized
double blind controlled trial to test different dosages of probiotics to determine what, if
any, effect probiotics have on AAD and CDAD (18). Participants received either
placebo, 50 billion CFU per day or 100 billion CFU per day. The CFU were in the form
of Lactobacillus acidolphus and Lactobacillus casei. Each participant’s respective dose
was given within 36 hours of receiving antibiotics. The probiotic or placebo was
received for 5 days and followed up for 21 days. Antibiotics that were administered
included, clindamycin, penicillin, and cephalosporin. This study was conducted in older
patients aged 50-70. Regardless of the treatment, each person received two pills to keep
the study double blinded. The trial took place between January 2009 and March 2009
and found a distinct dose response relationship. Higher probiotic usage led to lower
AAD. With CDAD, the dose response relationship was the same. Although higher doses
of probiotics led to fewer incidences of CDAD and AAD, there were participants in each
group who had AAD and CDAD. Twenty-three point eight (23.8) % of those in the
placebo group were positive for CDAD, 9.4% who received 50 billion CFU were positive
for CDAD, and only 1.2% who received 100 billion CFU were positive for CDAD. Both
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doses of probiotic also led to shorter duration and symptoms of AAD and CDAD. This
study only followed subjects for 21 days after treatment and AAD and CDAD can occur
up to 8 weeks after antibiotic therapy. This study is only indicative of the dose effect of
the certain strains that were used on CDAD and AAD. Therefore, other probiotics need
to be studied to show their dosage requirements for AAD and CDAD.
One particular probiotic, Florajen,® was tested in veterans for efficacy against
AAD in a pilot study at the Madison, Wisconsin Veterans Administration (39).
Florajen®, which contains the probiotic Lactobacillus acidolphus, was started on the
same day the antibiotics were started. After exclusion, 23 veterans were randomized to
treatment and 17 received placebo. One in the placebo group withdrew for his own
reasons. The amount of probiotic per capsule was not verified, but each capsule was said
to contain 20 billion CFU, and the treatment group received three doses per day. The
study found no major differences in clinical outcomes between the two groups. In
contrast, Hickson et al found promising effects of probiotics (22). Their study focused on
older patient’s response to probiotic bacteria while on antibiotics. All participants in the
study were at least 50 years old. If they were on high risk antibiotics, (clindamycin,
cephalosporins, or aminopenicillins) they were excluded. Within 48 hours of beginning
antibiotic treatment, probiotics were given, and stopped one week after antibiotics were
discontinued. A probiotic shake that contained, “Lactobacillus casei DN-114 001 (L
casei imunitass) (1.0×108 colony forming units/ml), S thermophilus (1.0×108 cfu/ml),
and L bulgaricus (1.0×107 cfu/ml)” was utilized. The placebo group received a sterilized
milkshake. One hundred grams were consumed twice a day half an hour before and one
to two hours after meals. Twenty-four samples were tested for Lactobacillus and the
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mean count was 2.2 x 108 CFU/ml. After analysis, the study concluded that probiotics
given twice daily for one week longer than antibiotic treatment is capable of preventing
AAD and CDAD with 12% of patients on probiotics developing AAD and 34% of the
control group developing AAD(P=.007). None of the participants in the treatment group
tested positive for C.difficile while 17% of those on placebo tested positive. So, based on
this study, with the proper length of administration of the probiotic, AAD and CDAD
rates can be reduced. One draw-back of the study is that high risk antibiotics were not
used.
Probiotics have also been studied in reducing the prevalence of diarrhea in
children. C.difficile is the most prevalent bacteria that causes nosocomial diarrhea in
children. Lactobacillus GG (LGG) is the strain that was tested in the prevention of
CDAD in the study published in 2001 by The Journal of Pediatrics (41). Diarrhea was
defined as 3 or more loose watery stools in a 24 hr period. LGG significantly reduced the
risk of CDAD in this study. Relative risk in the placebo group was 33.3% and the
treatment groups relative risk was 6.7%. Probiotics can be effective in children as well as
adults, which shows there is benefit for their use over a wide spectrum of ages.

Central Line Associated Blood Stream Infection
Probiotics have been studied with AAD, CDAD, and VAP, but there is little
research on the effects of probiotics on CLABSI prevention. CLABSI is defined as,
“bacteremia with a recognized pathogen when the organism isolated from blood culture is
not related to infection at another site; or isolation of a common skin contaminant from
two or more blood cultures associated with signs and symptoms of infection (fever,
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chills, or hypotension) that cannot be attributed to infection at another site” (33). The
line can become infected from microorganisms from a person’s own skin or from
unwashed hands and other outside sources (33). CLABSI is very common in the ICU.
Central lines are placed to provide life saving medical care and 250,000 infections occur
in hospitalized patients in the U.S every year from them (30, 33). Twenty-five percent of
those with central line infections die, which results in about 31,000 deaths annually in the
United States (33). CLABSI costs range from 960 million to 18.2 billion dollars annually
(42). Because multiple studies have shown probiotics to have no harm, and one study
found probiotics effective in treating central catheter infection as a secondary measure,
more studies should be conducted on probiotics and CLABSI. (27)

Lactobacillus plantarum
Specific bacteria strains found to be beneficial as probiotics are Lactobacillus and
Bifidobacteria. Hutt et al in the Journal of Applied Microbiology studied antagonistic
effects of select lactobacillus strains and bifidobacteria strains (23). The streak plate
method was used to test lactobacilli and bifidobacteria strands against two forms of
E.coli, Salmonella enteric, Shigella sonnei, H. pylori and C.difficile. The anti microbial
activity of the strains were tested in broth and agar plates. The study found that
Lactobacillus 299v had the strongest antagonistic property under microaerobic
conditions. Lactobacillus 299v has been studied in the fore-mentioned conditions.
One study by McNaught et al. investigated L. plantarum 299v effect on gut
barrier function, systemic inflammatory response syndrome (SIRS), and clinical
outcomes in critically ill patients; and the impact of HAIs were reduced (32). Proviva was
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given at 500 ml per day orally or 20 ml/hr continuous feed and 40 ml/2 hr bolus feed.
“Proviva is an oatmeal and fruit drink containing 5 x107 colony forming units per ml of
L. plantarum 299v” (31). Fifty-two patients were in the treatment group and 51 received
placebo. The study found that, although L. plantarum 299v reduces the amplitude of
SIRS, neither GI microflora nor clinical outcomes were affected. Based on this study,
the use of probiotics in critically ill patients to improve gut function cannot be
recommended. L. plantarum 299v may not have affected clinical outcomes in this set of
critically ill patients, but it was shown to be effective in the reduction of the impact of
nosocomial infections.
In 2008, Klarin et al. found that C.dificile colonization was lower in participants,
all on antibiotics, who received L.plantarum 299v than in a placebo group (24). A
fermented oatmeal gruel containing 8 x108 CFU/ml of L. plantarum 299v was given to
the study group. There were 22 participants in each group. The placebo group only
received oatmeal gruel with lactic acid so the pH matched that of the placebo group. The
antibiotics received were cephalosporines and carbapenems. Rectal fecal samples for C.
diff and L. plantarum 299v were taken and cultured twice a week for the duration of the
subjects stay in the ICU. Seventy-one fecal samples were analyzed in the L. plantarum
group and none of the participants were found to have C. difficile. C. difficile was found
in five fecal samples of the 80 analyzed in the placebo group. L. plantarum was seen in
four participants in inclusion samples and after more samples were taken during the
study, 18 out of 21 subjects had L. plantarum in the stool in the treatment group and only
three in the placebo group. This study found 19% of the placebo group developed
C.difficile bacteria while on antibiotics. L.plantarum recovery rate was high in the
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treatment group which shows that it is viable through the GI tract and the dose given was
adequate. The product was given in bolus feeds at six 100 ml doses at 12 hr intervals and
after that, 50 ml twice per day. Because none of the patients who were receiving the
L.plantarum 299v developed C. difficile bacterium, this study concludes that L.
plantarum 299v may counteract or prevent colonization of C. difficile in patients on
antibiotics.
L. plantarum 299v was also found to be beneficial in lowering the overall risk of
developing loose or watery stools while on antibiotics in a Lonnermark et al study (26).
Although loose watery stools were reported by participants, this did not meet the study
definition of diarrhea. The study defined diarrhea as three loose or watery stools per day
for two or more consecutive days. Because of this, it cannot be said that L. plantarum
299v reduces the risk of antibiotic associated diarrhea. The L. plantarum fruit drink
contained 1010 CFU, much lower than most other studies. C. difficile bacteria were also
analyzed in stool but no significance between the two groups were seen. Eighty
individuals were in the treatment group and 83 received placebo in this double blinded
placebo controlled trial. This study found no difference between the development of
diarrhea between the two groups most likely due to inadequate dosage of L. plantarum
299v.
As stated previously, it is believed that those who develop CDAD are at higher
risk of developing recurrent CDAD because intestinal flora loses its resistance to
colonization by C. difficile. Another study done in Sweden focused on recurrent CDAD.
Wultt et al conducted a prospective multicenter study and found no statistical significance
in CDAD recurrence between the two groups (45). There were 21 people who were
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included in the study and all had been diagnosed with C. difficile within the last two
months before treatment. There were only 11 participants in the treatment group and
recurrence of clinical symptoms was seen in four of them. Six of the nine in the placebo
group had recurrent symptoms. Because the study was so small, no definite conclusions
could be drawn.
L. plantarum in particular has also shown beneficial effects against VAP. A pilot
study done by Klarin et al found benefit of using L.plantarum 299 on reducing the
pathogenic bacteria in the oropharynx of intubated patients, which leads to VAP (24).
Fifty patients who were critically ill were randomized to receive oral mechanical
cleansing followed by application of .1% chlorhexidine (CHX) or an emulsion of
L.plantarum 299. A total of 21 patients were analyzed in the placebo group and 23 in the
probiotic group. Bacteria not present before the study were found in eight patients
receiving L.plantarum 299 and 13 receiving CHX. With this, the study concludes that
probiotics are safe to use and may be able to lower the rate of infection with harmful
microbes, which would lead to reduction of VAP cases. However the difference in VAP
was not conclusive in the study, one person in the treatment group contracted VAP and
three in the control group. Probiotics would be better to use because CHX has side effects
that include discoloration of teeth, burning sensation of the tongue, and irritation of the
mucosa. CHX also shows little activity against gram negative bacteria, which are the
main bacteria present in VAP. Probiotics, specifically L.plantarum strains, are stable and
have not been shown to contribute to the development of antibiotic resistance strains as
CHX does. “Besides offering a promising alternative to antiseptics like CHX, a probiotic
that adheres to the oral mucosa will be able to counteract potentially pathogenic bacteria
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24 hours a day, which is superior to the fairly short-term effect of orally applied chemical
agents” (24). From this study, it is evident that L. plantarum 299 reduces VAP cases and
is more appropriate for use than the CHX chemical.

Summary
Probiotics have promising effects in critically ill hospitalized patients. AAD,
CDAD, and VAP have been decreased with probiotic use in certain studies. Elderly
populations have also shown improved outcomes in hospital acquired infections with the
use of probiotics. This is important when studying probiotics in veterans because the
majority of them are older than 50. Although no differences in AAD/CDAD between
treatment group and placebo group were seen in the Wisconsin veteran population, from
the literature, it is clear that type and dose are very important in whether or not probiotics
are able to prevent these nosocomial infections. In AAD and CDAD, the research for
probiotics is promising, but longer follow up times of at least two months need to be
implemented to be sure these diarrheas did not occur. L. plantarum 299v specifically has
been proven to be effective in all of these infections with the exception of CLABSI.
Although CLABSI has not been well studied, the nature of probiotics allows the belief
that a positive outcome may occur in it as well. AAD, CDAD, VAP, and CLABSI are all
important hospital acquired infections that are costly and increase mortality risk. Billions
of dollars and thousands of lives can be saved annually if a method of prevention is
implemented. Probiotics have the potential to prevent these infections, and therefore,
future studies should be pursued.
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CHAPTER 3: METHODS
Research Design
In January 2011, the VAMC-Memphis performed a quality improvement study to
determine the effect of food form probiotics in the prevention of Clostridium difficile
infections, ventilator associated pneumonia, and central line associated bacteremia in
Medicine Intensive Care Unit patients. From this, a trend in the data showed decreased
rates of these hospital infections from the use of probiotics, but improvements could not
be found to be definitively because of probiotic implementation. With the collected data
from the quality improvement study, a retrospective cohort study was done on the change
in infection rates before, during, and after the implementation of the food form probiotic.
Infection rates three years prior to probiotic implementation will be analyzed (control 1),
the eight months during probiotic implementation and one year post supplement (control
2). The supplement used was GoodBelly Big Shot 50®, which contains Lactobacillus
299v and Bifidobacteria b107. This particular supplement was chosen because it was
food form, available in liquid form for easier flow through feeding tubes, and a smaller
amount could be used with a large amount of colony forming units (CFU). Seventy-four
individuals received 80 ml of probiotic containing 50 billion colony forming units once a
day, and treatment time ranged from 24 hours to eight months.
Inclusion criteria during the quality improvement study:


>18 years of age



Expected to be hospitalized for at least 24 hrs

Exclusion Criteria during the quality improvement study:
20



Immunocompromised



History of organ transplantation



Non functional GI tract



Acute pancreatitis



Receiving high dose steroids (>240 mg or equivalent of hydrocortisone)

Retrospective Cohort Study
Microsoft excel statistical analysis was used to analyze data. Specifically, chi
square test and t-test were used to gather a valid explanation between the independent and
dependent variables. Only patient information for those in the MICU who would have
met the criteria for the quality initiative improvement was analyzed. A chart review was
used to gather data. The independent variables being observed are patient demographics
(age,sex), and if antibiotics were being administered. During the protocol time frame,
extra independent variables include the duration of probiotic administration. The
dependent variable for all three time periods is rate of infection. The independent
variables in the three groups were compared to the rate of hospital associated infection
during the specific time period. Then, each group’s trends were compared to determine if
confounding factors played a role in decreased rate of infection. The significance was
measured at <.05. From this, it was determined if 50 billion CFU of Lactobacillus
plantarum 299v and Bifidobacteria b107 are able to reduce infection rates in MICU
patients hospitalized at the VAMC-Memphis.
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CHAPTER 4: RESULTS
A total of 3,274 patients were admitted to or transferred in to the MICU at the
VAMC-Memphis between January 1 2008 and March 31 2013. Of these, 1,935 were in
control 1 (the pre quality improvement group), 391 were admitted during the quality
improvement study group (QI), and 948 patients in control 2 (post quality improvement
study). Of the 1935 charts from control 1 reviewed, 851 of those patients (44%) admitted
did not meet improvement criteria and would not have received the food form probiotics.
Of the QI group, 317 were ineligible (81%), and 503(53%) in control 2 would not have
received probiotics. (Figure 1)
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The mean age of the groups was 65.8 ± 12.2, 66.3 ± 12.5and 61 ±12.1 for control 1, QI,
and controls 2 groups, respectively. There was no significant difference in age of the
patients among the three groups (control 1- control 2, p= 0.278; control 1-QI, p=0.183;
control 2-QI, p= 0.384). For antibiotic use, there was no significant difference between
control 1 and control 2, p= 0.47. There were, however, significantly fewer patients
eligible for probiotics receiving antibiotics in the QI group compared to control 1and
control 2, p= <.001 for both. (Table 1) There were significantly more female patients in
the control 2 group, p= <0.1. There were 1568 males total, 35 female included in the
study.
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Table 1. Demographics and characteristics

Age, mean ±
SD, years
Gender, M(F)
%F
Antibiotics

Control 1
(n= 1084)

QI
(n=74)

Control 2 (n=
445)

65.8 ± 12.2

66.3 ±
12.5
74 (0)
0%
47 (12%)

1067 (17)
1.6%
322 (30%)

61 ± 12.1

P value
(PQIQI)
0.183

P value
(QIPOQI)
0.384

P value
(PQIPOQI)
0.278

427 (18) 4.2%

0.16

0.5

<.01

127 (29%)

<0.1

<.01

0.47025945

Average
7.29 ±
LOP, days
12.2
PQI= Pre-quality improvement study, QI= quality improvement study, POQI = post
quality improvement study. LOP= length of probiotics

Using chi square analysis, infection rates for CLAB and CDAD were significantly lower
in the QI group. For CLAB, five patients in control 1(0.26%), zero in QI (0%), and one in
control 2 (0.11%) developed the HAI, p= 0.03. CDAD infections were 11 (0.57%), two
(0.51%), and eight (0.84%), for control 1, QI, and control 2, respectively (p= <0.05).
With VAP, infection rate was significantly lower in the control 2 group; 11 control 1
(0.57%), 2 QI (0.51%), and 3 control 2(0.21%) developed the infection, p = 0.01. (Table
2)
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Table 2. Infection Rates per incidence
Infection Type

Control 1
QI (n=391)
Control 2 (n=
P value
n=1935)
948)
VAP
11 (.57%)
2 (.51%)
3 (.32%)
.01
CLAB
5 (.26%)
0 (0%)
1 (.11%)
.03
CDAD
11 (.57%)
2 (.51%)
8 (.84%)
<.05
VAP= Ventilator Associated Pnemonia ; CLAB= Central Line Associated Bacteremia;
CDAD= Clostridium difficile Associated Diarrhea

When infection rates per 1000 line and vent days were compared, there was no
significant difference between the three groups. (Table 3)

Table 3. Infection Rates per line and vent day
Infection Type

Control 1
QI (n=391) Control 2
P value
(n=1935)
(n= 948)
VAP, % per 1000 vent days
3.3
2.2
3.9
.786
CLAB, % per 1000 line days
1.02
0
0.19
.479
VAP= Ventilator Associated Pnemonia ; CLAB= Central Line Associated Bacteremia;
CDAD= Clostridium difficile Associated Diarrhea
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CHAPTER 5: DISCUSSION
Findings

This study was unable to determine how large an effect 50 billion CFU of
Lactobacillus plantarum 299v and Bifidobacteria b107 given in food form had on HAI.
Rates for CLAB were significantly lower in the QI group per incidence (infections per
admit) but not per 1000 line days. At the current time, there are no other studies
published regarding the effect of probiotics in CLAB prophylaxis.

However, there have

been research articles regarding the prevention of CLAB and based on findings from
those studies, CLAB is a significant problem in the ICU.

There was no significant difference between VAP per 1000 vent days and percent
infection per incidence was significantly lower in the control 2 group. This was similar to
the results of the 2010 study on prophylaxis of VAP by Barraud et al which found
insignificant mortality rates between the probiotic group who received Ergyphilus®
capsules that contained 2 x 1010 CFU of Lactobacillus rhamnosus GG, Lactobacillus
casei, Lactobacillus acidolphus, and Bifidobacterium bifidum (25.3%) and the placebo
group (23.7%). However, it is important to note, that the post probiotics group had a
lower infection rate, so the probiotics might have had some lasting effect through
readmits. From research available, there have been no studies using food form probiotics
for prophylaxis of VAP.

Rates of CDAD were significantly lower in the QI group, p <.05. In the Hickson
et al study, a probiotic shake that contained, Lactobacillus casei, S thermophilus, and L
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bulgaricus was used. None of the participants in that study in the treatment group tested
positive for C.difficile while 17% of those on placebo tested positive.

Klarin et al determined L. plantarum 299v to counteract or prevent C.difficile in
patients on antibiotics. This study used an oatmeal gruel food form probiotic. Studies
have shown a dose dependent and time dependent relationship between probiotics and
decreased HAI. Where 50 billion CFU were provided in this QI study, only 800 million
CFU was given to patients in the 2008 study by Klarin et al and results still showed
CDAD prophylaxis. Average probiotic administration in that study was 5.5 days. The
average length of probiotics was 7.29 days in this QI study, ranging from one to 93 days.
This helps confirm the findings of our study that the probiotics ingested will prevent
CDAD.

During the QI study, a hand washing protocol was also emphasized on in the ICU.
This protocol continued after the probiotic study was discontinued. This could explain
why there was a lower infection rate in the control 2 group for VAP. This could also
explain why CLAB infection rates for the control 2 group were lower than control 1.
One study completed by Harris et al in 2011 among Pediatric ICU patients found that
improving hand hygiene, catheter care, and oral care reduced infections and saved the
hospital 12 million dollars annually (21).

Of the 391 patients admitted to the MICU during the quality initiative study, 74 of
them received probiotics (19%). Because less than 50% of patients received probiotics, it
is difficult to say whether probiotics led to decreased infection rates or other factors, such
as good hygiene practices, played a larger role. Although there were significantly more
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female patients in the control 2 group than the control 1 group, there has been no research
showing females to be at higher risk for HAI than males.

Significantly fewer patients during the QI time period eligible for probiotics
received antibiotics. This could mean that probiotics decreased infections, which
decreased the number of patients who needed antibiotics. Contrary to this, it could mean
that the control 1 and control 2 group were sicker and at higher risk for developing
infections than the QI group as it is widely known that broad spectrum antibiotic use is
one of the main causes of C. difficile associated diarrhea.

Limitations

While using the CPRS charting system, some problems were encountered. Some
admits had lengthy medical histories which crashed the system while attempting to load
their medical records. If the data needed was more than 3000 charts back, it was not
reviewed. For these patients, they were counted as not being candidates for probiotics.
This is a potential issue because these patients were included in the reported infection
rates, and there is no way to say for certain whether they met exclusion criteria or not. In
the quality improvement study, high dose steroids were considered 240 mg of
hydrocortisone or equivalent. Unfortunately, it was said that doctors determine what
dose of steroid is high on a case by case basis. Because of this, all admits who received
any type and amount of steroids were not included in the overall result analysis. This
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also caused some inconsistency with admits that would have been eligible to receive
probiotics.

Unfortunately, data connecting specific patients to specific infections was
unavailable. This would have strengthened the study if it was known if people actually
receiving probiotics developed the infection. It is also unknown what percent of the
patients eligible for probiotics were on the vent or had central lines placed which limits
the accuracy of rates reported.

Time was a major limiting factor in data collection. This retrospective review
should be completed again with more data collectors and with more time for data
collection. This way, more information can be gathered and more inquiries made to the
infection control department at the VA requesting more data.
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CHAPTER 6: CONCLUSION

From this retrospective cohort study, it was determined that Lactobacillus
plantarum 299v and Bifidobacterium b107 in food form played a role in the prevention of
hospital associated infections. Specifically CDAD infection rates were significantly
lower in the group that received probiotics. This study does not suggest that probiotics
reduce rates of VAP or CLAB. There was a significant difference between the groups in
antibiotic administration and a larger emphasis placed on hand washing during the QI and
control 2 group. Therefore, due to study limitations, differences between groups and
other hospital interventions concurrently with this study, this study is unable to determine
how large of a role probiotics play in the prevention of HAI. Further research using this
data should be done. By extracting the 19 patients who received probiotics and
evaluating them specifically for HAI, a more conclusive argument for the use of
probiotics in HAI may be determined.
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